Abstract 249P
Background
Abnormal uterine bleeding is the most common complaint in women attending to physicians, especially in the peri-menopausal and post-menopausal period which is reported to account for 70% of all gynecological consultations. The main aim of investigations for abnormal uterine bleeding is to rule out intrauterine pathology, particularly endometrial cancer or atypical hyperplasia.The study was aimed to conduct a systematic review and meta-analysis to evaluate the diagnostic accuracy of endometrial biopsy with Pipelle in women with abnormal uterine bleeding compared to D&C (reference standard) and sufficiency of the obtained endometrial tissue of two techniques.
Methods
Literature for studies published between 1965 and 2019 comparing the results of Pipelle with findings by D&C was searched. The QUADAS 2 tool was performed to evaluate the risk and applicability of each study. The diagnostic accuracy of Pipelle was evaluated through calculation of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio with pooled proportion.
Results
A total of 8 studies and 1675 patients were included in this meta-analysis. The pooled sensitivity of endometrial sampling by Pipelle was 70.9% (95%CI: 58.1%-81.1%) in endometrial tumor, 97.2% (95%CI: 95.5%-98.3%) in endometrial benign disease, and 94.4% (95%CI 92.7%-95.8%) in normal endometrium. The pooled specificity of Pipelle was 99.6% (95%CI: 99.0%-99.9%) in endometrial tumor, 74.7% (95% 56.4%-87.1%) in endometrial benign disease, and 90.0% (95%CI 75.5%-96.3%) in normal endometrium. The positive likelihood ratio by Pipelle in the diagnosis of endometrial tumor, benign disease and normal endometrium was 191.06 (95%CI 70.81-515.48), 28.86 (95%CI 15.10-55.19) and 9.573 (95%CI 4.28-21.40), while the negative likelihood ratio by Pipelle was 0.337 (95%CI 0.236-0.482), 0.241 (95%CI 0.131-0.444) and 0.07 (95%CI 0.04-0.11), respectively. The highest DOR 851.68 was achieved in the result of endometrial tumor.
Conclusions
Pipelle can be introduced as a suitable alternative of diagnostic curettage. When an adequate specimen is obtained, a positive test result is more accurate for ruling in disease than a negative test result for ruling it out.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients
Presenter: Sungmi Jung
Session: Poster display session
Resources:
Abstract
5P - Long-term prognostic effect of hormone receptor subtype on breast cancer
Presenter: Ki-tae Hwang
Session: Poster display session
Resources:
Abstract
6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel
Presenter: Yutaka Mizuno
Session: Poster display session
Resources:
Abstract
7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality
Presenter: Naoki Sato
Session: Poster display session
Resources:
Abstract
8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer ≥1cm
Presenter: Soeun Park
Session: Poster display session
Resources:
Abstract
10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer
Presenter: Seungtaek Lim
Session: Poster display session
Resources:
Abstract
11P - The prognosis of rare histopathologic subtype of breast cancer
Presenter: Soo Youn Bae
Session: Poster display session
Resources:
Abstract
12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study
Presenter: Yungil Shin
Session: Poster display session
Resources:
Abstract
13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry
Presenter: Shima Pashaei
Session: Poster display session
Resources:
Abstract
14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer
Presenter: Shinichiro Kashiwagi
Session: Poster display session
Resources:
Abstract